Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 ( n =231), TT2 ( n =668) without or with thalidomide and TT3 with added bortezomib ( n =30...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2013-01, Vol.27 (1), p.226-232
Hauptverfasser:	Usmani, S Z, Crowley, J, Hoering, A, Mitchell, A, Waheed, S, Nair, B, AlSayed, Y, vanRhee, F, Barlogie, B
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1059 692/308/409 692/699/67/1990/804 Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib Cancer Research Care and treatment Clinical Trials, Phase II as Topic - mortality Clinical Trials, Phase III as Topic - mortality Combined Modality Therapy Complications and side effects Critical Care Medicine Dosage and administration FDA approval Follow-Up Studies Gender Hematology Humans Intensive Internal Medicine Leukemia Medicine Medicine & Public Health Mortality Multiple myeloma Multiple Myeloma - mortality Multiple Myeloma - pathology Multiple Myeloma - therapy Neoplasm Staging Oncology original-article Patient outcomes Patients Prognosis Randomized Controlled Trials as Topic - mortality Ratios Stem cells Survival Rate Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!